Liquidia recently became the 30th drug manufacturer to restrict access to 340B pricing in the contract pharmacy setting.

Liquidia Becomes 30th Manufacturer to Limit Access to 340B Pricing in Contract Pharmacy Setting

Drugmaker Liquidia will implement contract pharmacy restrictions for a single drug that has a still-pending new drug application (NDA). The [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at